<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Consilium Medicum</journal-id><journal-title-group><journal-title xml:lang="en">Consilium Medicum</journal-title><trans-title-group xml:lang="ru"><trans-title>Consilium Medicum</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>Consilium Medicum</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2075-1753</issn><issn publication-format="electronic">2542-2170</issn><publisher><publisher-name xml:lang="en">Consilium Medicum</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">92736</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Optimizatsiya lecheniya osteoartroza: preparaty gialuronovoy kisloty</article-title><trans-title-group xml:lang="ru"><trans-title>Оптимизация лечения остеоартроза: препараты гиалуроновой кислоты</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Lila</surname><given-names>A. M</given-names></name><name xml:lang="ru"><surname>Лила</surname><given-names>А. М</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кафедра терапии №1 им. Э.Э.Эйхвальда с курсом ревматологии</p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en"></institution></aff><aff><institution xml:lang="ru">Санкт-Петербургская медицинская академия последипломного образования</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2008-07-15" publication-format="electronic"><day>15</day><month>07</month><year>2008</year></pub-date><volume>10</volume><issue>7</issue><issue-title xml:lang="en">VOL 10, NO7 (2008)</issue-title><issue-title xml:lang="ru">ТОМ 10, №7 (2008)</issue-title><fpage>124</fpage><lpage>128</lpage><history><date date-type="received" iso-8601-date="2021-12-28"><day>28</day><month>12</month><year>2021</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2008, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2008, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2008</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://consilium.orscience.ru/2075-1753/article/view/92736">https://consilium.orscience.ru/2075-1753/article/view/92736</self-uri><abstract xml:lang="ru"><p>Основными задачами лечения остеоартроза (ОА) являются уменьшение болевого синдрома, улучшение функции пораженных суставов, а также предотвращение или замедление прогрессирования заболевания. Решить эти задачи в настоящее время удается благодаря использованию нефармакологических и фармакологических методов, которые были предложены экспертным советом Европейской антиревматической лиги (EULAR) и представлены в виде рекомендаций по лечению ОА [1]. Современные методы лечения ОА Согласно рекомендациям EULAR, терапия ОА должна быть максимально индивидуализирована и учитывать факторы риска развития заболевания, выраженность болевого синдрома, наличие синовита, степень структурных повреждений и др. с широким использованием нефармакологических методов, в том числе программ образования больных, комплексов физических упражнений, мероприятия по снижению массы тела и т.д. Лекарственная терапия включает применение анальгетиков (парацетамола, трамадола, опиоидов), нестероидных противовоспалительных средств, а также структурно-модифицирующих препаратов медленного действия, оказывающих симптоматический эффект и способных модифицировать структуру хряща, – хондроитина сульфата, глюкозамина сульфата, диацереина, неомыляемых соединений авокадо/сои и гиалуроновой кислоты (ГК). При этом внедрение в клиническую практику препаратов ГК рассматривается как качественный скачок в лечении ОА, учитывая их потенциальную способность эффективно подавлять болевой синдром и улучшать функциональную активность больных</p></abstract></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Jordan K.M, Arden N.K, Doherty M et al. EULAR Recommendations 2003: anevidence based approach to the management of knee osteoarthritis: Report or a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESTISIT). Ann Rheum Dis 2003; 62: 1145–55.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Беленький А.Г. Препараты гиалуроновой кислоты в лечении остеоартроза. М., 2005.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Лила А.М. Остеоартроз коленных суставов: лечение с позиций доказательной медицины. Новые Санкт - Петербургские врачебные ведомости. 2006; 1 (35): 38–44.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Laurent T.C, Laurent U.B, Fraser J.R. The structure and function of hyaluronan: An overview. Immunol Cell Biol 1996; 74 (2): 1–7.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Ward P.D, Thibeault S.L, Gray S.D. Hyaluronic acid: its role in voice. J Voice 2002; 16 (3): 303–9.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Wobig M, Dickhut A, Maier R, Vetter G. Viscosupplementation with hylan G-F 20: a 26-week controlled trial of efficacy and safety in the osteoarthritic knee. Clin Ther 1998; 20 (20): 410–23.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Belenkiy A, Denisov L, Lila A et al. Comparative efficacy of three and five intra - articular injections of sodium hyaluronate (Ostenil) in the treatment of knee osteoarthritis – a 12-month study. Ann Rheum Dis 2006; 65 (Suppl. II): 223.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Sandell L.J, Aigner T. Articular cartilage and changes in arthritis. An introduction: cell biology of osteoarthritis. Arthritis Res 2001; 3: 107–13.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Pelletier J.P, Martel-Pelletier J, Abramson S.B. Osteoarthritis, an inflammatory disease: potential implication for the selection of new therapeutic targets. Arthritis Rheum 2001; 44: 1237–47.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Tanimoto K, Ohno S, Fujimoto K et al. Proinflammatory cytokines regulate the gene expression of hyaluronic acid synthetase in cultured rabbit synovial membrane cells. Connect Tissue Res 2001; 42: 187–95.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Knudson W, Loeser R.F. CD44 and integrin matrix receptors participate in cartilage homeostasis. Cel Mol Life Sci 2002; 59: 36–44.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Aihara S, Murakami N, Ishii R et al. Effects of sodium hyaluronate on the nociceptive response of rats with experimentally induced arthritis. Nip Yakur Zasshi 1992; 100: 359–65.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Moore A.R, Willoughby D.A. Hyaluronan as a drug delivery system for diclofenac: a hypothesis for mode of action. Int J Tissue React 1995; 17: 153–6.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Dougados M, Nguyen M, Listrat V, Amor B. High molecular weight sodium hyaluronate (hyalectin) in osteoarhtritis of the knee: a 1 year placebo controlled trial. Osteoarthritis Cartilage 1993; 21: 97–103.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Listrat V, Ayral X, Patarnello F et al. Arthroscopic evaluation of potential structure modifyting activity of hyaluronan (Hyalgan) in osteoarthritis of the knee. Osteoarthritis Cartilage 1997; 5: 153–60.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Lussier A, Cividino A.A, Mc Farlane C.A et al. Viscosupplementation with Hylan for the treatment of osteoarthritis findings from clinical practice in Canada. J Rheumatol 1996; 23 (1): 579–85.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Lahmander L.S, Dalen N, Englund G. Intra - articular hyaluronan injections in the treatment of osteoarthritis of the knee: a randomized, double blind, placebo - controlled multicentre trial. Ann Rheum Dis 1996; 55: 424–31.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Stove J, Puhl W. Overview of clinical and experimental use of hyaluronic acid in gonarthrosis. Z Orthop Ihre Grenzgeb 1999; 137 (5): 393–9.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Belcher C, Yaqub R, Fawthrop F et al. Synovial fluid chondroitin and keratan sulphate epitopes, glycosaminoglycans, and hyaluronan in arthritic and normal knees. Ann Rheum Dis 1997; 56: 299–307.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Conrozier T, Vignon E. Is there evidence to support the inclusion of viscosupplementation in the treatment paradigm for patients with hip osteoarthritis. Clin Exp Rheumatol 2005; 23 (5): 711–6.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Puttick M.P, Wade J.P, Chalmers A et al. Acute local reactions after intraarticular hylan for osteoarthritis of the knee. J Rheumatol 1996; 23 (5): 945–6.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Kirvan J. Is there a place for intra - articular hyaluronate in osteoarthritis of the knee? Knee 2001; 8: 93–101.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Henderson E.B, Smith E.C, Pegley F, Blake D.R. Intra - articular injections of 750 kD hyaluronan in the treatment of osteoarthritis: a randomised single centre double - blind placebo - controlled trial of 91 patients demonstrating lack of efficacy. J Rheumatol 1996; 23 (5): 944–5.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Tikiz C, Unlu Z, Sener A, Efe M. Comparison of the efficacy of lower and higher molecular weight viscosupplementation in the treatment of hip osteoarthritis. Clin Rheumathol 2005; 24: 244–50.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Tortorella M.D, Malfait A.M, Deccico C, Arner E. The role of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) in a model of cartilage degradation. Osteoarthritis Cartilage 2001; 9: 539–52.</mixed-citation></ref></ref-list></back></article>
